ARTICLE | Company News
Pherin, N.V. Organon deal
July 28, 1997 7:00 AM UTC
The companies will develop Pherin's vomeropherins to treat premenstrual syndrome and anxiety. The compounds are used topically within the nasal passage to activate the vomeronasal organ, which triggers a nerve impulse to the hypothalamus. Organon received worldwide rights to the compounds in return for upfront payments, research funding and potential milestones, as well as royalties.
While Pherin has tested the compounds' effects on the hypothalamus in humans, the companies will need to conduct additional preclinical work in both indications. ...